FDA OKs Subcutaneous Lecanemab for Early AD – Medscape

1. FDA OKs Subcutaneous Lecanemab for Early AD  Medscape
2. FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease  Biogen
3. Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug  MedCity News
4. US FDA Approves BioArctic Partnership’s Maintenance Injection for Alzheimer’s Disease  富途牛牛
5. FDA Approved: An Injectable Version of Alzheimer’s Drug Leqembi  Being Patient

Continue Reading